How to buy Pyxis Oncology stock (Pyxis Oncology)

Pyxis Oncology is a biotechnology business based in the US. Pyxis Oncology shares (PYXS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.69 – an increase of 0.6% over the previous week. Pyxis Oncology employs 54 staff and has a trailing 12-month revenue of around $16.1 million.

Our top picks for where to buy Pyxis Oncology stock

Buy Pyxis Oncology stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Pyxis Oncology stock price (NASDAQ: PYXS)

Use our graph to track the performance of PYXS stocks over time.

Pyxis Oncology shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$1.69
52-week range	$1.49 - $6.85
50-day moving average more info button	$3.06
200-day moving average more info button	$3.75
Wall St. target price	$10.67
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.06

Is it a good time to buy Pyxis Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pyxis Oncology price performance over time

Historical closes compared with the close of $1.69 from 2024-12-20

1 week (2024-12-16)	0.60%
1 month (2024-11-22)	-11.05%
3 months (2024-09-23)	-53.06%
6 months (2024-06-21)	-49.85%

1 year (2023-12-22)	0.30%
2 years (2022-12-23)	32.03%
3 years (2021-12-23)	9.81
5 years (2019-12-19)	N/A

Pyxis Oncology financials

Revenue TTM	$16.1 million
Gross profit TTM	$0
Return on assets TTM	-21.06%
Return on equity TTM	-39.34%
Profit margin	0%
Book value	$2.59
Market Capitalization more info button	$90.4 million

TTM: trailing 12 months

Pyxis Oncology share dividends

We're not expecting Pyxis Oncology to pay a dividend over the next 12 months.

You may also wish to consider:

Pyxis Oncology share price volatility

Over the last 12 months, Pyxis Oncology's shares have ranged in value from as little as $1.49 up to $6.85. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pyxis Oncology's is 1.276. This would suggest that Pyxis Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put Pyxis Oncology's beta into context you can compare it against those of similar companies.

• Kinnate Biopharma Inc (KNTE.US): 1.34
• Turning Point Therapeutics (TPTX.US): -0.1941
• Agios Pharm (AGIO.US): 0.751

Pyxis Oncology overview

Pyxis Oncology, Inc. , a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate.

Frequently asked questions

What percentage of Pyxis Oncology is owned by insiders or institutions?
Currently 24.536% of Pyxis Oncology shares are held by insiders and 56.55% by institutions. How many people work for Pyxis Oncology?
Latest data suggests 54 work at Pyxis Oncology. When does the fiscal year end for Pyxis Oncology?
Pyxis Oncology's fiscal year ends in December. Where is Pyxis Oncology based?
Pyxis Oncology's address is: 321 Harrison Avenue, Boston, MA, United States, 02118 What is Pyxis Oncology's ISIN number?
Pyxis Oncology's international securities identification number is: US7473241013